About e lmrga + nata mab bcmm
BCMA- and CD3-directed bispecific antibody
Used for
- Treats adults with relapsed or refractory multiple myeloma after at least four prior treatment lines.
Usual adult dose
Subcutaneous treatment starts with step-up doses, then a weekly dose; after 24 weeks, dosing may become every two weeks if responding. Specialist-supervised.
Common side effects
- Cytokine release syndrome
- Infections
- Low blood-cell counts
- Injection-site reactions
Important warnings
- Can cause serious cytokine release syndrome and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome.
- Treatment requires step-up dosing and monitoring after early doses; hospitalization may be required.
- Can cause serious infections and reduced blood-cell counts.
- May cause fetal harm; effective contraception is recommended during treatment and for six months afterward.
Pregnancy
May harm an unborn baby. Pregnancy status is checked before treatment; effective contraception is recommended during treatment and for six months after the last dose.
Breastfeeding
Avoid breastfeeding during treatment and for six months after the last dose.
Interactions
- No major drug interactions are established; medicines that suppress immune function may increase infection risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.